Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
|Articles|December 1, 1998
The American Journal of Managed Care
- December 1998
- Volume 4
- Issue 12
Trends in Costs of Percutaneous Transluminal Coronary Angioplasty
Advertisement
Articles in this issue
almost 28 years ago
Evaluation of Anemiaalmost 28 years ago
The Role of Clinical Practice Guidelines in Disease Managementalmost 28 years ago
Pharmacist Compensation for Ambulatory Patient Care ServicesAdvertisement
Related to this article
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
Delphi consensus guides dermatology on spotting CTCL vs atopic dermatitis before/after dupilumab, using biopsy plus T-cell clonality testing and safer treatment switches.
Rosacea is likely missed, not rare, in skin of color, as low suspicion and hard-to-see redness delay diagnosis, said Hilary Baldwin, MD.
Hidradenitis suppurativa diagnosis often takes 7 to 10 years, and patients with skin of color often present with tunnels and scarring already in place.
In HIV, lymphoma survival tracks tumor stage and CD4 count, not viral suppression, a Spanish cohort shows.
Polyphenols show lab promise for endometriosis, but human evidence is thin, and the best resveratrol pain trial was negative.
Those using e-cigarettes were more likely to develop cataracts, and those receiving cataract surgery less likely to develop depression and anxiety.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Drug Price Negotiations Yield Uneven Out-of-Pocket Savings
2
A New Mechanism for DME in the BRUNELLO Trial: Donald J. D’Amico, MD
3
Lymphoma Outcomes Hinge on Oncology, Not Viral Load In People With HIV
4
New Mechanism of DME Treatment Highlights Clinical Trial Updates
5